XENCOR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.98 USD | +3.90% |
|
+8.71% | -5.89% |
| Apr. 16 | BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating | MT |
| Apr. 09 | Xencor Names Bart Cornelissen as Chief Financial Officer | MT |
Presenter SpeechPeter Lawson (Analysts)My name is Peter Lawson, I'm one of the biotech analyst...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.98
USD
Average target price
36.18
USD
Spread / Average Target
+81.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.89% | 1.23B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XNCR Stock
- News Xencor, Inc.
- Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11
